JP2022537384A5 - - Google Patents
Info
- Publication number
- JP2022537384A5 JP2022537384A5 JP2021575509A JP2021575509A JP2022537384A5 JP 2022537384 A5 JP2022537384 A5 JP 2022537384A5 JP 2021575509 A JP2021575509 A JP 2021575509A JP 2021575509 A JP2021575509 A JP 2021575509A JP 2022537384 A5 JP2022537384 A5 JP 2022537384A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864413P | 2019-06-20 | 2019-06-20 | |
| US62/864,413 | 2019-06-20 | ||
| PCT/US2020/038760 WO2020257665A1 (en) | 2019-06-20 | 2020-06-19 | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537384A JP2022537384A (ja) | 2022-08-25 |
| JP2022537384A5 true JP2022537384A5 (https=) | 2023-06-08 |
| JPWO2020257665A5 JPWO2020257665A5 (https=) | 2023-06-08 |
Family
ID=71528047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575387A Pending JP2022537551A (ja) | 2019-06-20 | 2020-06-19 | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
| JP2021575509A Pending JP2022537384A (ja) | 2019-06-20 | 2020-06-19 | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575387A Pending JP2022537551A (ja) | 2019-06-20 | 2020-06-19 | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12447171B2 (https=) |
| EP (2) | EP3986403A1 (https=) |
| JP (2) | JP2022537551A (https=) |
| KR (2) | KR20220050874A (https=) |
| CN (2) | CN114727996A (https=) |
| AU (2) | AU2020296179A1 (https=) |
| BR (2) | BR112021025537A2 (https=) |
| CA (2) | CA3143719A1 (https=) |
| IL (2) | IL289110A (https=) |
| MX (2) | MX2021015993A (https=) |
| WO (2) | WO2020257665A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3597741A1 (en) | 2012-04-27 | 2020-01-22 | Duke University | Genetic correction of mutated genes |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| US10676726B2 (en) | 2015-02-09 | 2020-06-09 | Duke University | Compositions and methods for epigenome editing |
| EP4089175A1 (en) | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| EA201891317A3 (ru) | 2015-11-30 | 2019-04-30 | Дьюк Юниверсити | Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения |
| US20190127713A1 (en) | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| WO2018017754A1 (en) | 2016-07-19 | 2018-01-25 | Duke University | Therapeutic applications of cpf1-based genome editing |
| WO2019144061A1 (en) | 2018-01-19 | 2019-07-25 | Duke University | Genome engineering with crispr-cas systems in eukaryotes |
| US20240141341A1 (en) * | 2021-03-01 | 2024-05-02 | Duke University | Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness |
| WO2022215995A1 (ko) * | 2021-04-05 | 2022-10-13 | 주식회사 피노바이오 | 4'-티오-5-아자-2'-디옥시사이티딘 및 베네토클락스의 병용 요법 |
| JP2024517318A (ja) * | 2021-05-11 | 2024-04-19 | アッヴィ・インコーポレイテッド | アザシチジンと組み合わせて骨髄異形成症候群の処置に使用されるベネトクラクス投与レジメン |
| CN117651556A (zh) * | 2021-05-11 | 2024-03-05 | 艾伯维公司 | 与cyp3a抑制剂和阿扎胞苷联合治疗骨髓增生异常综合征的维奈托克给药方案 |
| US20250312327A1 (en) * | 2021-10-14 | 2025-10-09 | Pharos Ibio Co., Ltd | Composition for combination therapy, comprising 2,3,5-substituted thiophene compound |
| TW202340177A (zh) | 2021-12-30 | 2023-10-16 | 美商拜歐米富士恩股份有限公司 | 作為 flt3抑制劑之吡嗪化合物 |
| IL317874A (en) | 2022-06-24 | 2025-02-01 | Tune Therapeutics Inc | Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3782612B1 (en) * | 2008-05-15 | 2023-11-08 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| SI3137169T1 (sl) | 2014-05-01 | 2022-04-29 | Celgene Quanticel Research, Inc. | Inhibitorji lizin specifične demetilaze-1 |
| EA201790376A1 (ru) | 2014-09-05 | 2017-08-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы лизин-специфической деметилазы-1 |
| WO2016040238A1 (en) | 2014-09-08 | 2016-03-17 | Celgene Corporation | Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody |
| PT3362066T (pt) | 2015-10-15 | 2021-11-16 | Celgene Corp | Terapia de combinação para tratar malignidades |
| US10695352B2 (en) | 2015-10-15 | 2020-06-30 | Celgene Corporation | Combination therapy for treating malignancies |
| EP3371152B1 (en) | 2015-11-05 | 2020-12-23 | Celgene Quanticel Research, Inc. | Compositions comprising an inhibitor of lysine specific demethylase-1 having a pyrimidine ring and its use in the treatment of cancer |
| CN109462980B (zh) * | 2016-03-15 | 2022-02-08 | 奥莱松基因组股份有限公司 | 用于治疗血液恶性肿瘤的lsd1抑制剂的组合 |
| US20200069677A1 (en) * | 2016-12-09 | 2020-03-05 | Constellation Pharmaceuticals, Inc. | Markers for personalized cancer treatment with lsd1 inhibitors |
| EP4201399A3 (en) | 2017-06-30 | 2023-08-09 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide |
| WO2019012328A1 (en) | 2017-07-09 | 2019-01-17 | Biosight Pharma | ANTICANCER POLY THERAPY |
| TWI848030B (zh) | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
-
2020
- 2020-06-19 BR BR112021025537A patent/BR112021025537A2/pt not_active IP Right Cessation
- 2020-06-19 WO PCT/US2020/038760 patent/WO2020257665A1/en not_active Ceased
- 2020-06-19 AU AU2020296179A patent/AU2020296179A1/en not_active Abandoned
- 2020-06-19 CN CN202080058723.0A patent/CN114727996A/zh active Pending
- 2020-06-19 JP JP2021575387A patent/JP2022537551A/ja active Pending
- 2020-06-19 MX MX2021015993A patent/MX2021015993A/es unknown
- 2020-06-19 CA CA3143719A patent/CA3143719A1/en active Pending
- 2020-06-19 JP JP2021575509A patent/JP2022537384A/ja active Pending
- 2020-06-19 EP EP20737778.9A patent/EP3986403A1/en active Pending
- 2020-06-19 WO PCT/US2020/038772 patent/WO2020257671A1/en not_active Ceased
- 2020-06-19 US US17/620,545 patent/US12447171B2/en active Active
- 2020-06-19 BR BR112021025375A patent/BR112021025375A2/pt active Search and Examination
- 2020-06-19 KR KR1020227001609A patent/KR20220050874A/ko not_active Ceased
- 2020-06-19 CA CA3143711A patent/CA3143711A1/en active Pending
- 2020-06-19 MX MX2021015992A patent/MX2021015992A/es unknown
- 2020-06-19 EP EP20737783.9A patent/EP3986404A1/en not_active Withdrawn
- 2020-06-19 CN CN202080057984.0A patent/CN115066243A/zh active Pending
- 2020-06-19 KR KR1020227001605A patent/KR20220024639A/ko not_active Ceased
- 2020-06-19 AU AU2020297596A patent/AU2020297596A1/en not_active Abandoned
- 2020-06-19 US US17/620,541 patent/US20220249528A1/en active Pending
-
2021
- 2021-12-19 IL IL289110A patent/IL289110A/en unknown
- 2021-12-19 IL IL289115A patent/IL289115A/en unknown